|
ZUFSP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.06009999947909E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.88470000001195E-06 |
| Normal-vs-Stage2 |
1.576000E-04 |
| Normal-vs-Stage3 |
1.3950999999679E-07 |
| Normal-vs-Stage4 |
1.26980000003662E-06 |
| Stage1-vs-Stage2 |
4.532400E-01 |
| Stage1-vs-Stage3 |
6.964300E-02 |
| Stage1-vs-Stage4 |
1.439360E-01 |
| Stage2-vs-Stage3 |
6.199600E-01 |
| Stage2-vs-Stage4 |
6.284600E-01 |
| Stage3-vs-Stage4 |
9.522200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.40939999951451E-07 |
| Normal-vs-AfricanAmerican |
5.278000E-03 |
| Normal-vs-Asian |
3.861600E-03 |
| Caucasian-vs-AfricanAmerican |
5.637600E-01 |
| Caucasian-vs-Asian |
4.646600E-01 |
| AfricanAmerican-vs-Asian |
9.941200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.83620000041118E-07 |
| Normal-vs-Female |
9.15340000018361E-07 |
| Male-vs-Female |
3.920000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.69240000000137E-05 |
| Normal-vs-Age(41-60Yrs) |
2.24580000041108E-07 |
| Normal-vs-Age(61-80Yrs) |
4.21410000006617E-07 |
| Normal-vs-Age(81-100Yrs) |
1.815650E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.977700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.643160E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.125400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.806600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.247800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.529600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.478030E-01 |
| Classical-VS-Follicular |
3.294200E-01 |
| Classical-VS-Other |
3.257400E-01 |
| Classical-VS-Normal |
4.77750000005273E-06 |
| Tall-VS-Follicular |
5.080600E-01 |
| Tall-VS-Other |
7.849200E-01 |
| Tall-VS-Normal |
1.72125999999828E-05 |
| Follicular-VS-Other |
6.314000E-01 |
| Follicular-VS-Normal |
2.39289999999226E-05 |
| Other-VS-Normal |
6.084100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.90080000020509E-08 |
| Normal-vs-N1 |
5.227100E-04 |
| N0-vs-N1 |
5.066000E-01 |
|
|
